Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents

Bibliography

• Ge Y, Tiwari A, Li S. Nanomedicine – bridging the gap between nanotechnology and medicine. Adv Mat Lett 2011;2:1–2
   Google Scholar
• Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine 2014;9:467–83
   PubMed Web of Science ®Google Scholar
• Song G, Darr DB, Santos CM, et al. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res 2014;20:6083–95
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Strychor S, Joseph E, et al. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res 2007;13:7217–23
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004;53:329–36
   PubMed Web of Science ®Google Scholar
• Salmaso S, Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv 2013;2013:374252
   PubMedGoogle Scholar
• Schell RF, Sidone BJ, Caron WP, et al. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomedicine 2014;10:109–17
   PubMed Web of Science ®Google Scholar
• Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008;13:248–60
   PubMed Web of Science ®Google Scholar
• Lichtnekert J, Kawakami T, Parks WC, et al. Changes in macrophage phenotype as the immune response evolves. Curr Opin Pharmacol 2013;13:555–64
   PubMed Web of Science ®Google Scholar
• Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005;11:8230–4
   PubMed Web of Science ®Google Scholar
• Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J 2012;14:282–95
   PubMed Web of Science ®Google Scholar
• Rabanel JM, Aoun V, Elkin I, et al. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. Curr Med Chem 2012;19:3070–102
   PubMed Web of Science ®Google Scholar
• Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother 2004;58:168–72
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387–92
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73:2412–17
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136–51
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci USA 2013;110:18632–7
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751–60
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater 2013;12:958–62
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Torchilin V, Patri AK, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 2012;18:3229–41
   PubMed Web of Science ®Google Scholar
• Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res 2011;3:219–25
   PubMedGoogle Scholar
• Stirland DL, Nichols JW, Miura S, et al. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release 2013;172:1045–64
   PubMed Web of Science ®Google Scholar
• Vaage J, Barbera-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994;73:1478–84
   PubMed Web of Science ®Google Scholar
• Oberoi HS, Nukolova NV, Kabanov AV, et al. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 2013;65:1667–85
   PubMed Web of Science ®Google Scholar
• Newman MS, Colbern GT, Working PK, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999;43:1–7
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014;66:2–25
   PubMed Web of Science ®Google Scholar
• Hume DA, Ross IL, Himes SR, et al. The mononuclear phagocyte system revisited. J Leukoc Biol 2002;72:621–7
   PubMed Web of Science ®Google Scholar
• Pangburn TO, Petersen MA, Waybrant B, et al. Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics. J Biomech Eng 2009;131:074005
   Web of Science ®Google Scholar
• Wickham T, Reynolds J, Drummond D, et al. Preclinical safety and activity of MM-302, a HER2-targeted liposomal doxorubicin designed to have an improved safety and efficacy profile over approved anthracyclines. Cancer Res 2010;70(24 Suppl):P3–14
   Google Scholar
• Dobrovolskaia MA, Aggarwal P, Hall JB, et al. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008;5:487–95
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2:469–78
   PubMed Web of Science ®Google Scholar
• Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, et al. Nanoparticles and the Immune System. Endocrinology 2010;151:458–65
   PubMed Web of Science ®Google Scholar
• Egusquiaguirre SP, Igartua M, Hernandez RM, et al. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol 2012;14:83–93
   PubMed Web of Science ®Google Scholar
• Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. As Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003;14:239–46
   PubMed Web of Science ®Google Scholar
• Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012;17:160–6
   PubMed Web of Science ®Google Scholar
• Zhang H, Gong W, Wang ZY, et al. Preparation, characterization, and pharmacodynamics of thermosensitive liposomes containing docetaxel. J Pharm Sci 2014;103:2177–83
   PubMed Web of Science ®Google Scholar
• Sabatini P, Sill MW, O’Malley D, et al. A phase 2 trial of paclitaxel polyglumex in recurrent or persistent ovarian or primary peritoneal cancer: A Gynecologic Oncologic Group study. Gynecol Oncol 2008;111:455–60
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater 2009;8:15–23
   PubMed Web of Science ®Google Scholar
• Barua S, Rege K. Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots. Small 2009;5:370–6
   PubMed Web of Science ®Google Scholar
• Toy R, Peiris PM, Ghaghada KB, et al. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) 2014;9:121–34
   PubMed Web of Science ®Google Scholar
• Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1992;1104:95–101
   PubMed Web of Science ®Google Scholar
• Charrois GJ, Allen TM. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 2003;1609:102–8
   PubMed Web of Science ®Google Scholar
• Chu KS, Hasan W, Rawal S, et al. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine 2013;9:686–93
   PubMed Web of Science ®Google Scholar
• Xu J, Wong DH, Byrne JD, et al. Future of the particle replication in nonwetting templates (PRINT) technology. Angew Chem Int Ed Engl 2013;52:6580–9
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Hayes ME, et al. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008;97:4696–740
   PubMed Web of Science ®Google Scholar
• Muthu MS, Feng SS. Nanopharmacology of liposomes developed for cancer therapy. Nanomedicine (Lond) 2010;5:1017–19
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691–743
   PubMed Web of Science ®Google Scholar
• Levchenko TS, Rammohan R, Lukyanov AN, et al. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 2002;240:95–102
   PubMed Web of Science ®Google Scholar
• Kraft JC, Freeling JP, Wang Z, et al. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 2014;103:29–52
   PubMed Web of Science ®Google Scholar
• Katz MG, Fargnoli AS, Williams RD, et al. Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications. Hum Gene Ther 2013;24:914–27
   PubMed Web of Science ®Google Scholar
• Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998;5:930–7
   PubMed Web of Science ®Google Scholar
• Krasnici S, Werner A, Eichhorn ME, et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003;105:561–7
   PubMed Web of Science ®Google Scholar
• Martins S, Tho I, Reimold I, et al. Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies. Int J Pharm 2012;439:49–62
   PubMed Web of Science ®Google Scholar
• Lockman PR, Koziara JM, Mumper RJ, et al. Nanoparticle surface charges alter blood–brain barrier integrity and permeability. J Drug Target 2004;12:635–41
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496–504
   PubMed Web of Science ®Google Scholar
• Sadzuka Y, Hirotsu S, Hirota S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 1998;127:99–106
   PubMed Web of Science ®Google Scholar
• Pal A, Khan S, Wang YF, et al. Preclinical safety, pharmacokinetics and anti-tumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res 2005;25:31–41
   Google Scholar
• Dark GG, Calvert AH, Grimshaw R, et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2005;23:1859–66
   PubMed Web of Science ®Google Scholar
• Xiong W, Peng L, Chen H, et al. Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy. Int J Nanomed 2015;10:2985–96
   PubMed Web of Science ®Google Scholar
• Chu KS, Schorzman AN, Finniss MC, et al. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials 2013;34:8424–9
   PubMed Web of Science ®Google Scholar
• La-Beck NM, Zamboni BA, Gabizon A, et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 2012;69:43–50
   PubMed Web of Science ®Google Scholar
• Gusella M, Bononi A, Modena Y, et al. Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old. Cancer Chemother Pharmacol 2014;73:517–24
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Maruca LJ, Strychor S, et al. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res 2011;21:158–65
   PubMed Web of Science ®Google Scholar
• Falandry C, Brain E, Bonnefoy M, et al. Impact of geriatric vulnerability parameters on pegylated liposomal doxorubicin (PLD) tolerance and outcome in elderly patients with metastatic breast cancer: Results of the DOGMES multicenter phase II GINECO trial. Eur J Cancer 2013;49:2806–14
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009;22:1041–50
   PubMed Web of Science ®Google Scholar
• Lloberas J, Celada A. Effect of aging on macrophage function. Exp Gerontol 2002;37:1325–31
   PubMed Web of Science ®Google Scholar
• La-Beck N, Wu H, Infante J, et al. The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents. J Clin Oncol 2010;28:e13003
   Google Scholar
• Song G, Wu H, La-Beck N, et al. Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and Optisomal topotecan (TLI) in rats. Cancer Res 2010;70:3700
   Google Scholar
• Zamboni WC, Strychor S, Maruca L, et al. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther 2009;86:519–26
   PubMed Web of Science ®Google Scholar
• Wu H, Ramanathan RK, Zamboni BA, et al. Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies. J Clin Pharmacol 2012;52:180–94
   PubMed Web of Science ®Google Scholar
• Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996;59:32–40
   PubMed Web of Science ®Google Scholar
• Twelves CJ, O’Reilly SM, Coleman RE, et al. Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer 1989;60:938–41
   PubMed Web of Science ®Google Scholar
• Gabizon A, Isacson R, Rosengarten O, et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2008;61:695–702
   PubMed Web of Science ®Google Scholar
• La-Beck N, Tzemach D, Schmeeda H, et al. Evaluation of the relationship between patient factors and the reduction in clearance of pegylated liposomal doxorubicin. ASCO Annual Meeting. J Clin Oncol 2009;27:2548
   Google Scholar
• Caron WP, Lay JC, Fong AM, et al. Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. J Pharmacol Exp Ther 2013;347:599–606
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Ruhstaller T, Lerch S, et al. Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2011;22:80–5
   PubMed Web of Science ®Google Scholar
• Volk LD, Flister MJ, Chihade D, et al. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 2011;13:327–38
   Google Scholar
• Ewer MS, Martin FJ, Henderson C, et al. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31:161–81
   PubMed Web of Science ®Google Scholar
• Cainelli F, Vallone A. Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma. Biologics 2009;3:385–90
   PubMedGoogle Scholar
• Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711–16
   PubMed Web of Science ®Google Scholar
• Stern ST, Hall JB, Yu LL, et al. Translational considerations for cancer nanomedicine. J Control Release 2010;146:164–74
   PubMed Web of Science ®Google Scholar
• Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005;10:205–14
   PubMed Web of Science ®Google Scholar
• Eckes J, Schmah O, Siebers JW, et al. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer 2011;11:337
   PubMed Web of Science ®Google Scholar
• Ping M, Mumper RJ. Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review. Nano Today 2013;8:313–31
   PubMed Web of Science ®Google Scholar
• Yurkovetskiy AV, Fram RJ. XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development. Curr Bioactive Compounds 2011;7:15–20
   Google Scholar
• Yurkovetskiy AV, Fram RJ. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv Drug Deliv Rev 2009;61:1193–202
   PubMed Web of Science ®Google Scholar
• Eliasof S, Lazarus D, Peters CG, et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci USA 2013;110:15127–32
   PubMed Web of Science ®Google Scholar
• Posey JA, Saif MW, Carlisle R, et al. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res 2005;11:7866–71
   PubMed Web of Science ®Google Scholar
• Oh GS, Kim HJ, Shen A, et al. Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies. Electrolyte Blood Press 2014;12:55–65
   PubMedGoogle Scholar
• Sheikh-Hamad D, Timmins K, Jalali Z. Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 1997;8:1640–4
   PubMed Web of Science ®Google Scholar
• Liu D, He C, Wang AZ, et al. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine 2013;8:3309–19
   PubMed Web of Science ®Google Scholar
• Devarajan P, Tarabishi R, Mishra J, et al. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res 2004;24:2193–200
   PubMed Web of Science ®Google Scholar
• Boulikas T. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 2009;18:1197–218
   PubMed Web of Science ®Google Scholar
• Mylonakis N, Athanasiou A, Ziras N, et al. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIb/IV) non-small-cell lung cancer. Lung Cancer 2010;68:240–7
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Antoniou D, Dimitroulis J, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 2010;21:2227–32
   PubMed Web of Science ®Google Scholar
• Caron WP, Song G, Kumar P, et al. Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. Clin Pharmacol Ther 2012;91:802–12
   PubMed Web of Science ®Google Scholar
• Petschauer JS, Madden AJ, Kirschbrown WP, et al. The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents. Nanomedicine 2015;10:447–63
   PubMed Web of Science ®Google Scholar